Evidence map›Paper›PMID 42497354›Full record

ArticleEmerging microbes & infections2026

Efficiency of nanovaccines compared with antibiotic therapy in the prevention and immunomodulation of listeriosis.

Carmen Alvarez-Dominguez, Ricardo Calderón-Gonzalez, David Salcines-Cuevas, Vicente Soriano, María Ubeda, Noemi Montoya, Jorge Calvo-Montes, Marco Marradi, Javier Freire, Javier Gomez-Roman and 5 more

Abstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Carmen Alvarez-DominguezMEDONLINE Group, Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja (UNIR), Logroño, Spain.ORCID 0000-0002-4585-6959
Ricardo Calderón-GonzalezInstituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
David Salcines-CuevasInstituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Vicente SorianoMEDONLINE Group, Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja (UNIR), Logroño, Spain.
María UbedaMEDONLINE Group, Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja (UNIR), Logroño, Spain.
Noemi MontoyaMEDONLINE Group, Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja (UNIR), Logroño, Spain.
Jorge Calvo-MontesInstituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Marco MarradiDepartment of Chemistry "Ugo Schiff", University of Florence, Firenze, Italy.
Javier FreireInstituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Javier Gomez-RomanInstituto de Investigación Marqués de Valdecilla (IDIVAL), Santander, Spain.
Elena Gonzalez-LopezServicio de Inmunología, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Javier Gonzalo Ocejo-VinyalsServicio de Inmunología, Hospital Universitario Marqués de Valdecilla, Santander, Spain.
Jose Maria MarimonServicio de Microbiología, Instituto de Investigación Sanitaria Biodonostia, Gipuzkoa, Spain.
Elena VazquezMEDONLINE Group, Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja (UNIR), Logroño, Spain.
Víctor Moreno-TorresMEDONLINE Group, Facultad de Ciencias de la Salud, Universidad Internacional de La Rioja (UNIR), Logroño, Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although the main antimicrobial therapy for adult and neonatal listeriosis is ampicillin, prophylactic treatments are currently lacking. We compared the efficiency of nanovaccines with prenatal or postnatal ampicillin treatments in pregnant female mice during the development of neonatal listeriosis. Nanovaccines prepared with gold nanoparticles and listeriolysin O (LLO) or glyceraldehyde-3-phosphate dehydrogenase (GAPDH) peptides and inoculated into pregnant females, prevented neonatal listeriosis and the appearance of comorbidities, better than pre or postnatal ampicillin treatment. Evaluation of the ability of nanovaccines as immunomodulators of blood cells in patients with listeriosis, revealed the strong and specific immunogenic capacity of the use of GAPDH nanovaccines as putative immunotherapies in listeriosis.

Indexed as

AmpicillinAnti-Bacterial AgentsListeriosisNanovaccinesAnimalsBacterial ToxinsFemaleGlyceraldehyde-3-Phosphate DehydrogenasesGoldHeat-Shock ProteinsHemolysin ProteinsHumansImmunomodulationListeria monocytogenesMetal NanoparticlesMiceAmpicillinAnti-Bacterial AgentsBacterial ToxinsGlyceraldehyde-3-Phosphate DehydrogenasesGoldHeat-Shock ProteinsHemolysin ProteinshlyA protein, Listeria monocytogenesNanovaccinesadjuvantsantibioticsglyceraldehyde-3-phosphate-dehydrogenaseGold glyconanoparticlesnanovaccines

Identifiers

PMID42497354
PMCPMC13403572

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.